Cogent Biosciences Inc (COGT)
$9.52
+0.3
(+3.25%)▲
Performance
- $9.21$9.56$9.52
3.26%
Downside
Day's Volatility :3.66%
Upside
0.42%
- $3.67$13.36$9.52
61.45%
Downside
52 Weeks Volatility :72.53%
Upside
28.74%
Returns
| Period | Cogent Biosciences Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 53.16% | 6.5% | 0.0% |
6 Months | 110.74% | 7.1% | 0.0% |
1 Year | -24.24% | 9.8% | 0.0% |
3 Years | 47.76% | 14.2% | -20.2% |
Highlights
Market Capitalization | 1.0B |
Book Value | $2.09 |
Earnings Per Share (EPS) | -2.49 |
Wall Street Target Price | 16.7 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -38.43% |
Return On Equity TTM | -65.7% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | -100.0% |
Gross Profit TTM | -121.6M |
EBITDA | -225.0M |
Diluted Eps TTM | -2.49 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.28 |
EPS Estimate Next Year | -2.25 |
EPS Estimate Current Quarter | -0.52 |
EPS Estimate Next Quarter | -0.49 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 75.42%
Technicals Summary
Sell
Neutral
Buy
Cogent Biosciences Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Cogent Biosciences Inc | 13.83% | 110.74% | -24.24% | 47.76% | 349.76% |
 Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
 Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
 Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
 Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Cogent Biosciences Inc | NA | NA | NA | -2.28 | -0.66 | -0.38 | NA | 2.09 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Cogent Biosciences Inc | Buy | $1.0B | 349.76% | NA | 0.0% |
Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Cogent Biosciences Inc
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 85.8%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 138.7%
Institutional Holdings
Kynam Capital Management, LP
8.89%State Street Corporation
7.98%FMR Inc
7.28%BlackRock Inc
7.00%Point72 Asset Management, L.P.
6.98%COMMODORE CAPITAL LP
6.72%
Company Information
unum therapeutics is a cambridge, massachusetts-based cellular therapeutics company ushering in a new wave of innovation in cancer immunotherapy. unum was built to transform cancer treatment through the discovery, development and commercialization of novel antibody-coupled cellular immunotherapies. unum has built an antibody-coupled t-cell receptor (actr) platform that, when combined with tumor-specific antibodies, directs an individual’s cytotoxic t-lymphocytes (ctls) to kill tumor cells. in contrast to other approaches that hit a single target and treat a narrow set of tumors, unum’s approach is not restricted by antigens and may have applications for treating many types of cancers. unum’s vision: a single cell therapy that can augment the activity of multiple antibodies to treat many different cancers. unum's lead program based on actr technology is currently in phase i clinical testing to assess safety and efficacy in certain forms of leukemia and lymphoma. in parallel, unum is act
Organization | Cogent Biosciences Inc |
Employees | 164 |
CEO | Mr. Andrew R. Robbins M.B.A. |
Industry | Health Technology |
Discover More
A Spac I Acquisition Corp
$9.52
+3.25%
Keyarch Acquisition Corp
$9.52
+3.25%
Connexa Sports Technologies Inc
$9.52
+3.25%
Us Value Etf
$9.52
+3.25%
First Wave Biopharma Inc
$9.52
+3.25%
Global X Msci Next Emerging
$9.52
+3.25%
Fat Projects Acquisition Corp
$9.52
+3.25%
Capital Link Global Fintech
$9.52
+3.25%
Applied Uv Inc
$9.52
+3.25%